Funding
The High-Tech Gründerfonds (HTGF) and Life Science Fonds Esslingen are jointly investing a total of €700,000 in Amedrix GmbH, which was founded in January 2009 to develop acellular medical products based on animal collagen for wound healing and the reconstruction of soft tissues.
The new investment will enable the company to gain approval for its first medical products and to set up its own production operations.
The main advantage of using animal collagen implants is that they can be varied in size, form and consistency. Furthermore, the collagen matrices have excellent biocompatibility. In the body, the implants provide scaffolds which are colonised by the patient’s own cells.
Amedrix has set up the technology for collagen and implant production and has tested its first prototypes for functionality and biocompatibility. The new financing now enables the company to take the necessary steps to obtain approval for its first products and then to set up production.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
